Boehringer Ingelheim Pharmaceuticals and Eli Lilly have received approval from the US Food and Drug Administration (FDA) for Synjardy (empagliflozin and metformin hydrochloride) tablets to treat type 2 diabetes (T2D).

According to Boehringer, Synjardy is the third product containing empagliflozin to have received FDA approval, after Jardiance (empagliflozin) and Glyxambi (empagliflozin / linagliptin).

Empagliflozin is a sodium glucose co-transporter-2 (SGLT2) inhibitor, which removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

"Our alliance is proud to offer a diverse portfolio of treatments that can help patients throughout their diabetes journey."

Synjardy is a combination of two medicines, including empagliflozin and metformin, with complementary mechanisms of action that will control blood glucose in people with T2D.

The tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with empagliflozin and metformin.

Boehringer Ingelheim Pharmaceuticals president and CEO Paul Fonteyne said: "Synjardy is now the fifth FDA-approved medicine to emerge from the BI-Lilly Diabetes alliance pipeline in the last four years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"No two people with diabetes are alike, and every experience is different. Our alliance is proud to offer a diverse portfolio of treatments that can help patients throughout their diabetes journey."

Metformin is an initial treatment for T2D, which reduces glucose production by the liver and its absorption in the intestine.

In 2011, Boehringer Ingelheim and Eli Lilly established partnership in diabetes to focus on compounds representing several of the largest diabetes treatment classes.